Invesco Ltd. Invests $28,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Invesco Ltd. purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 11,215 shares of the biotechnology company’s stock, valued at approximately $28,000.

Other institutional investors have also added to or reduced their stakes in the company. ExodusPoint Capital Management LP purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter worth approximately $26,000. Commonwealth Equity Services LLC bought a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $36,000. Charles Schwab Investment Management Inc. bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth $82,000. JPMorgan Chase & Co. increased its position in shares of Aclaris Therapeutics by 942.0% during the fourth quarter. JPMorgan Chase & Co. now owns 88,320 shares of the biotechnology company’s stock valued at $219,000 after buying an additional 79,844 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $383,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Trading Down 11.1 %

Shares of NASDAQ:ACRS opened at $1.28 on Tuesday. Aclaris Therapeutics, Inc. has a 12 month low of $0.95 and a 12 month high of $5.17. The company has a market cap of $138.60 million, a price-to-earnings ratio of -2.46 and a beta of 0.42. The company has a 50-day moving average price of $1.46 and a 200-day moving average price of $2.25.

Analyst Ratings Changes

Several research analysts have commented on ACRS shares. Scotiabank began coverage on shares of Aclaris Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a research report on Tuesday, March 18th. They set an “overweight” rating on the stock. Finally, StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $11.67.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.